US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gladstone Investment Corp

25.35

+0.08000.32%

Volume:25.91K

Turnover:656.82K

Market Cap:- -

PE:- -

High:25.40

Open:25.32

Low:25.32

Close:25.27

Loading ...

Overview Company News Filings

Gladstone Investment Acquires Nielsen-Kellerman

MT Newswires Live

Gladstone Investment Corporation Enters Into Definitive Agreement to Acquire the Ricardo Defense Business

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Is KKR & Co. (KKR) Poised to Weather Any Macroeconomic Environment?

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Press Release: Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Should You Hold Apellis Pharmaceuticals (APLS)?

Gladstone Investment Prices $110 Million Debt Offering

MT Newswires Live

Gladstone Investment Corporation Prices Public Offering of 7.875% Notes due 2030

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GAINI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GAINI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GAINI\",,,,,undefined,":{"symbol":"GAINI","market":"US","secType":"STK","nameCN":"Gladstone Investment Corp","latestPrice":25.35,"timestamp":1750276800000,"preClose":25.27,"halted":0,"volume":25907,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed Juneteenth National Independence Day","change":0.08,"latestTime":"06-18 16:00:00 EDT","open":25.32,"high":25.4,"low":25.32,"amount":656816.9839,"amplitude":0.003166,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750406400000},"marketStatusCode":7,"adr":0,"listingDate":1733893200000,"exchange":"NASDAQ","adjPreClose":25.27,"dividendRate":0.03787,"volumeRatio":2.872618857793098},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GAINI\",,,,,undefined,":{"symbol":"GAINI","floatShares":0,"roa":"3.81%","roe":"13.17%","lyrEps":0,"volumeRatio":2.872618857793098,"shares":0,"dividePrice":0.96,"high":25.4,"amplitude":0.003166,"preClose":25.27,"low":25.32,"week52Low":24.6,"pbRate":"0.00","psRate":"0.00","week52High":25.53,"institutionHeld":0,"latestPrice":25.35,"eps":0,"divideRate":0.03787,"volume":25907,"delay":0,"ttmEps":0,"open":25.32,"prevYearClose":25.37,"prevWeekClose":25.27,"prevMonthClose":25.06,"prevQuarterClose":25.4,"fiveDayClose":25.31,"twentyDayClose":25.31,"sixtyDayClose":25.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GAINI\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492446077","title":"Gladstone Investment Acquires Nielsen-Kellerman","url":"https://stock-news.laohu8.com/highlight/detail?id=2492446077","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492446077?lang=en_us&edition=fundamental","pubTime":"2024-12-20 22:06","pubTimestamp":1734703610,"startTime":"0","endTime":"0","summary":"Gladstone Investment (GAIN) said Friday it acquired Nielsen-Kellerman a day earlier.Financial terms were not disclosed.The acquisition was completed in partnership with Nielsen-Kellerman's leadership ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GAINL","GAIN","BK4135","GAINI","GAINZ"],"gpt_icon":0},{"id":"2492148245","title":"Gladstone Investment Corporation Enters Into Definitive Agreement to Acquire the Ricardo Defense Business","url":"https://stock-news.laohu8.com/highlight/detail?id=2492148245","media":"ACCESSWIRE","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492148245?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:30","pubTimestamp":1734643800,"startTime":"0","endTime":"0","summary":"MCLEAN, VA / ACCESSWIRE / December 19, 2024 / Gladstone Investment Corporation   announced today that on December 13, 2024, it, along with Proteus Enterprises LLC, signed a definitive agreement to acquire Ricardo Defense, Inc. .Final closing is anticipated for December 31, 2024, once all customary closing conditions have been satisfied. Gladstone Investment will provide equity and senior secured debt to complete the transaction.RDI, based in Troy, Michigan, is an engineering services and systems integration firm focused on helping Department of Defense customers solve technical hurdles to modernizing, managing, and maintaining the fleet. \"We are looking forward to working with Proteus, President Chet Gryczan and the team at RDI to build on the company's established presence and to continue bringing innovative solutions to its customers,\" said Christopher Lee, Senior Managing Director of Gladstone Investment.\"We are thrilled to be adding another quality portfolio company to Gladstone In","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Vsck1EjLN5EnTAnhHgeSMA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/98bce022622f092c3c3720ef8ace7bb4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Vsck1EjLN5EnTAnhHgeSMA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/98bce022622f092c3c3720ef8ace7bb4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gladstone-investment-corporation-enters-definitive-213000841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GAIN","GAINI","GAINZ","GAINL","BK4135"],"gpt_icon":0},{"id":"2492269771","title":"Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","url":"https://stock-news.laohu8.com/highlight/detail?id=2492269771","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492269771?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:38","pubTimestamp":1734608280,"startTime":"0","endTime":"0","summary":"OCU410 has a very favorable safety and tolerability profile. No serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis. MALVERN, Pa., Dec. 19, 2024  -- Ocugen, Inc.  , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board  for the OCU410 ArMaDa clinical trial recently convened and approved continuation of the second phase of the Phase 1/2 study. OCU410  is a novel modifier gene therapy candidate being developed for geographic atrophy  secondary to dry age-related macular degeneration .“The DSMB assessed data on 15 subjects from Phase 2. Initial data indicates that OCU410appears to besafe and well-tolerated,” said Peter Chang, MD, FACS, Co-President and Partner of the Massachusetts Eye Research and Surgery Institut","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ni2Gj4rdBtzY6gwpwHU4NQ--~B/aD01NzE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e445aee5167658b52b538c8467aeffb3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ni2Gj4rdBtzY6gwpwHU4NQ--~B/aD01NzE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e445aee5167658b52b538c8467aeffb3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/data-safety-monitoring-board-reviews-113800039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4563","BK4139","GAINI","BK4568","OCGN"],"gpt_icon":0},{"id":"2492133752","title":"Is KKR & Co. (KKR) Poised to Weather Any Macroeconomic Environment?","url":"https://stock-news.laohu8.com/highlight/detail?id=2492133752","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492133752?lang=en_us&edition=fundamental","pubTime":"2024-12-18 23:39","pubTimestamp":1734536366,"startTime":"0","endTime":"0","summary":"RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” third quarter 2024 investor letter.A copy of the letter can bedownloaded here. During the third quarter, the markets performed strongly with the Russell 1000 Growth Index  and the S&P 500 index returning 3.19% and 5.89% respectively and RPX returning 3.73%. A weaker-than-expected jobs report that raised fears of a coming recession caused the RLG to drop 8.8% from the end of June to the fifth of August, giving the quarter a rocky start. As China passed a significant stimulus package and the Fed began its rate-cutting cycle with a 0.50% decrease to a goal of 4.75%-5.00%, those losses quickly reversed. In addition, please check the fund’s top five holdings to know its best picks in 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1K4RsmKfcvijwJxHpJMbYg--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/0b6ff3b243138a7aa40299eaa33251ee","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1K4RsmKfcvijwJxHpJMbYg--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/0b6ff3b243138a7aa40299eaa33251ee"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kkr-co-kkr-poised-weather-153926700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0980610538.SGD","LU0106831901.USD","KKR","LU1935042488.USD","LU1935042991.SGD","IE00B3QW5Z07.USD","LU1201861249.SGD","LU1935042215.USD","BK4588","IE00B64PRP62.GBP","LU0314104364.USD","BK4135","LU1935043536.SGD","IE00BGHQF748.EUR","LU1935043023.USD","LU0130102774.USD","GAINI","BK4585","LU1668664300.SGD","LU1791807156.HKD","LU0648001328.SGD"],"gpt_icon":0},{"id":"2492907751","title":"Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies","url":"https://stock-news.laohu8.com/highlight/detail?id=2492907751","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492907751?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:22","pubTimestamp":1734524520,"startTime":"0","endTime":"0","summary":"- Improvements Across Measures of Behavior, Function, Cognition and Movement -. - Expediting Plans to Advance CT1812 into Late-Stage Trials -. PURCHASE, N.Y., Dec. 18, 2024  -- Cognition Therapeutics, Inc. , a clinical-stage company developing drugs that treat neurodegenerative disorders, announced topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies .“These topline results exceeded our expectations and support the broad potential of CT1812 across neurodegenerative disorders,” stated Anthony Caggiano, M.D., Ph.D., Cognition’s chief medical officer and head of R&D. “Analysis of CT1812’s activity in DLB will continue as additional data become available. We look","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l.sJq8HYeZEZDz2e4ohWQA--~B/aD03MDt3PTI1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/84deb1d7dd06342dbaa15670f8542aa5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l.sJq8HYeZEZDz2e4ohWQA--~B/aD03MDt3PTI1MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/84deb1d7dd06342dbaa15670f8542aa5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cognition-therapeutics-announces-positive-results-122200827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CGTX","GAINI","CAF","LU0205193047.USD","LU0240877869.USD","DLB","BK4007","LU0240878834.USD","LU0345774631.USD","LU0205194284.USD","LU0345774391.USD","LU0348723411.USD","BK4139","LENZ","BK4097"],"gpt_icon":1},{"id":"2491691589","title":"Press Release: Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491691589","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491691589?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:05","pubTimestamp":1734357900,"startTime":"0","endTime":"0","summary":"BOSTON and LONDON, Dec. 16, 2024  -- Akari Therapeutics, Plc  today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings in the U.S. and Europe.Akari Therapeutics, Plc  is a biotechnology company developing advanced therapies for autoimmune, oncology and inflammatory diseases. Akari has two lead assets, investigational nomacopan and an antibody drug conjugate  platform. Nomacopan is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","AKTX","LENZ","BK4080","ADC","GAINI","NQmain","BK4139","BK4007"],"gpt_icon":0},{"id":"2490599387","title":"Should You Hold Apellis Pharmaceuticals (APLS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2490599387","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490599387?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:35","pubTimestamp":1734014148,"startTime":"0","endTime":"0","summary":"PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. equity markets fluctuated during the summer and partially reversed their year-to-date gains. The S&P 1500 Health Care Index appreciated 6.1% in the third quarter, outperforming the S&P 500, which gained 5.9%. While the fund advanced in the quarter, it underperformed the index. Stock selection within medtech and pharmaceuticals contributed to the most value. Relative performance was negatively impacted by security selection in biotechnology and health care providers and services, as well as underweights in life sciences tools and services. In addition, please check the fund’s top five holdings to know its best picks in 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l74pAKCPjAqCg.k7tJ.L4g--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/dbb21807ed45b512c3b93ac5fa3618e5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l74pAKCPjAqCg.k7tJ.L4g--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/dbb21807ed45b512c3b93ac5fa3618e5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hold-apellis-pharmaceuticals-apls-143548998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","APLS","NQmain","BK4588","GAINI","MNQmain","NVIW.SI","SQQQ","TQQQ","PSQ","BK4585","USJW.SI","LU1093756168.USD","BK4505","QID","LU1093756325.SGD",".IXIC","USAW.SI","TSYW.SI","BK4139"],"gpt_icon":1},{"id":"2490836922","title":"Gladstone Investment Prices $110 Million Debt Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2490836922","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490836922?lang=en_us&edition=fundamental","pubTime":"2024-12-11 17:36","pubTimestamp":1733909781,"startTime":"0","endTime":"0","summary":"Gladstone Investment  said late Tuesday it has priced a public offering of $110.0 million worth of 7.875% notes due 2030.The company said it also granted underwriters a 30-day option to purchase up to $16.5 million worth of additional notes to cover any over-allotments.The transaction is expected to close on Dec. 17. The company said it intends to use proceeds from the offering to repay debt, to fund new investments, and for general corporate purposes.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GAINZ","GAINL","GAINI","GAIN","BK4135"],"gpt_icon":0},{"id":"2490074983","title":"Gladstone Investment Corporation Prices Public Offering of 7.875% Notes due 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2490074983","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490074983?lang=en_us&edition=fundamental","pubTime":"2024-12-11 08:00","pubTimestamp":1733875200,"startTime":"0","endTime":"0","summary":"MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Gladstone Investment Corporation   today announced that it priced a public offering of $110.0 million aggregate principal amount of 7.875% Notes due 2030  on December 10, 2024. The Notes will mature on February 1, 2030 and may be redeemed in whole or in part at any time or from time to time at the Company's option on or after February 1, 2027. The Notes will bear interest at a rate of 7.875% per year payable quarterly on February 1, May 1, August 1 and November 1 of each year, beginning February 1, 2025. The Company also granted the underwriters a 30-day option to purchase up to an additional $16.5 million in aggregate principal amount of Notes to cover overallotments, if any. The Company expects to list the Notes on the Nasdaq Global Select Market under the trading symbol \"GAINI\" within 30 days of issuance. Oppenheimer & Co. Inc., B. Riley Securities, Inc. and Lucid Capital Markets, LLC are acting as joint book-running managers for this of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/s4ZUb9fhs85cpQ1UtSzQvg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e796f7d196d7148f7c56c84c10178561","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/s4ZUb9fhs85cpQ1UtSzQvg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e796f7d196d7148f7c56c84c10178561"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gladstone-investment-corporation-prices-public-000000253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GAINZ","GAINL","GAINI","GAIN","BK4135"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GAINI\",params:#limit:5,,,undefined,":[{"date":"2025-05-13","symbol":"GAINI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747166400000,"name":null,"time":"Post Market","dateTimestamp":1747108800000,"actualEps":null},{"date":"2025-04-15","symbol":"GAINI","amount":0.4921875,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-15","defaultRemindTime":1744723800000,"name":"Gladstone Investment Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-01","payableDate":"2025-04-15","currency":"USD","dateTimestamp":1744689600000,"payDate":"2025-05-01"},{"date":"2025-02-12","symbol":"GAINI","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739394000000,"name":null,"time":"Post Market","dateTimestamp":1739336400000,"actualEps":null},{"date":"2025-01-15","symbol":"GAINI","amount":0.24609,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-15","defaultRemindTime":1736951400000,"name":"Gladstone Investment Corp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-01","payableDate":"2025-01-15","currency":"USD","dateTimestamp":1736917200000,"payDate":"2025-02-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GAINI\",market:\"US\",,,undefined,":[{"executeDate":"2025-01-15","recordDate":"2025-01-15","paymentDate":"2025-02-01","value":0.24609,"currency":"USD"},{"executeDate":"2025-04-15","recordDate":"2025-04-15","paymentDate":"2025-05-01","value":0.4921875,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GAINI\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.1667,"hold":0.6667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.1667,"analysts":6,"updateTime":1747281600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GAINI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GAINI","date":"2025-01-08","current":12.541077,"percent":0,"low":12.541077,"twenty":12.6277,"median":12.661387,"eighty":12.752822,"high":12.954943,"avg":12.702511,"sd":0.108259,"marketCap":478053331},"quantilePoints":[{"date":"2024-12-27","current":12.637325,"twenty":12.6277,"median":12.632513,"eighty":12.764372,"marketCap":481722197},{"date":"2025-01-03","current":12.743198,"twenty":12.63155,"median":12.702292,"eighty":12.752822,"marketCap":485757951},{"date":"2025-01-08","current":12.541077,"twenty":12.6277,"median":12.661387,"eighty":12.752822,"marketCap":478053331}],"updateTime":1750335650793}}}